|
Match
|
Document |
Document Title |
|
|
7371744 |
Biologically active methylene blue derivatives
A phenothiazinium compound of Formula (I):
wherein:
A and B each independently is
in which R′ and R″ each independently is a linear, branched or cyclic hydrocarbon group, or R′ and...
|
|
|
7335652 |
Neurofibrillary labels
Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, by (i) introducing into the subject a...
|
|
|
7323461 |
Use of methylene blue and related compounds to prevent or reverse an exaggerated hemodynamic reaction
The present invention relates to the use of the dye methylene blue (MB) or a related compound to prevent or reverse an exaggerated hemodynamic reaction in animals in need thereof, including humans....
|
|
|
7148216 |
Combinations of drugs for the treatment of neoplastic disorders
The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts...
|
|
|
7074782 |
Carbamate caspase inhibitors and uses thereof
This invention provides caspase inhibitors of formula I:
wherein Z is oxygen or sulfur; R 1 is hydrogen, —CHN 2 , R, CH 2 OR, CH 2 SR, or —CH 2 Y; Y is an electronegative leaving group; R 2...
|
|
|
6953794 |
Inhibition of tau-tau association
A composition and use thereof for the prophylaxis or treatment of Alzheimer's disease, motor neurone disease, Lewy body disease, Pick's disease or progressive supranuclear palsy. The composition...
|
|
|
6846816 |
Combinations of drugs for the treatment of neoplastic disorders
The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts...
|
|
|
6747024 |
Heterocyclic compounds and their use as medicines
The present invention relates to new heterocyclic derivatives having an inhibitory activity on calpains and/or a trapping activity on reactive oxygen species, of formula in which A, X, Y, R1, R...
|
|
|
6743817 |
Substituted fused pyrroleimines and pyrazoleimines
Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R 1 and R 2 are defined herein. These compounds are highly selective agonists,...
|
|
|
6703401 |
Compounds, their preparation and use
The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by clear receptors, in particular the...
|
|
|
6583138 |
Heterocyclic-ring condensed benzothiazine compound
The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate....
|
|
|
6485750 |
Phenothiazine in prill form and method for making the same
Phenothiazine and its derivatives products are provided with a minimal level of fines or dust as a result of forming such products in prill form. The prills are generally spherical. Also provided...
|
|
|
6482822 |
N-(iminomethyl)amines derivatives, their preparation, their use as medicines and compositions containing them
The invention concerns novel N-(iminomethyl)amine derivatives comprising in their skeleton the aminophenylamine, oxodiphenylamine, carbazole, phenazine, phenoxazine or oxodiphenyl motif, their use...
|
|
|
6468971 |
Maintaining kidney function during surgery or trauma
Kappa-opioid agonists prevent the impairment of renal function otherwise caused by the combination of gaseous anesthesia and surgery or severe trauma. Not only do these agents preserve renal...
|
|
|
6436437 |
Covalent polar lipid conjugates with neurologically active compounds for targeting
This invention herein describes a method of facilitating the entry of drugs into cells and tissues at physiologically protected sites at pharmicokinetically useful levels and also a method of...
|
|
|
6420405 |
Pharmaceutical composition for angiotensin II-mediated diseases
This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula wherein R 1 is...
|
|
|
6348460 |
1,2,3-thiadiazole derivatives, plant disease controller and method for using the same
A 1,2,3-thiadiazole derivative represented by general formula (I): [wherein R 1 is hydrogen atom, halogen atom, (C 1 -C 6 ) alkyl, phenyl, etc., R 2 is the following group (A) or group (B): ...
|
|
|
6346529 |
Antiviral therapy using thiazine dyes
A method for using thiazine dyes, especially methylene blue, alone or in combination with low levels of light, to selectively inactivate or inhibit intracellular replication of specific viruses,...
|
|
|
6306437 |
Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
Psychogenic impotence can be ameliorated without substantial undesirable side effects by administration of apomorphine and an antiemetic agent in an amount sufficient to substantially reduce nausea...
|
|
|
6159966 |
Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
A compound of formula (I) ##STR1## its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates, wherein R 3 , R 4 , R...
|
|
|
6159965 |
Anti-emetic pharmaceutical compositions containing methotrimeprazine
A non-sedating anti-emetic composition in oral unit dosage form comprising from 1 to 5 mg of methotrimeprazine per unit dosage, or in unit dosage form for parenteral administration comprising from...
|
|
|
6075020 |
Method of regulating immune function
Disclosed herein is a method of treating an immune system dysfunction in a mammal by administering a prolactin reducer and a prolactin enhancer at a predetermined time or times.
|
|
|
6001832 |
[1,2,4]triazolo[4,3-a]quinoxalinone derivatives, their preparation and use
The present invention relates to [1,2,4]triazolo[4,3-a]quinoxalinone compounds of the formula ##STR1## wherein R 1 is POX'X" or alkyl substituted with COX' or POX'X", and X' and X" independently...
|
|
|
5994349 |
3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives
Phenothiazines of the formula: ##STR1## where R 1 is H or --COOR, where R is selected from the group consisting of branched or unbranched alkyl groups containing from 1 to 4 carbon atoms, and...
|
|
|
5942410 |
Composition and method for staining cellular DNA, comprising thiazine derivative metabisulfite and methanol or ethanol
A composition and method for staining cellular DNA are disclosed. The composition of the present invention is an aqueous alcoholic solution that includes a cationic stain, a metabisulfite, and an...
|
|
|
5854240 |
Methylene blue for the treatment or prophylaxis of encephalopathy caused by ifosfamide
The encephalopathy caused by ifosfamide and similarly acting compounds can be prevented or treated by the administration of methylene blue or another compound which is able to oxidize a reduced...
|
|
|
5827644 |
Thiazine dyes used to inactivate HIV in biological fluids
A method for using thiazine dyes, especially methylene blue, alone or in combination with low levels of light, to selectively inactivate or inhibit intracellular replication of specific viruses,...
|
|
|
5693638 |
Method of treating a migraine headache
The present invention is directed to the treatment of a migraine headache with a composition containing leuko methylene blue as the active ingredient.
|
|
|
5663167 |
Antipsychotic composition and method of treatment
A method for treating a serious psychotic mental illness includes the step of administering to a patient in need of such treatment a combination of (i) an α 2 -adrenergic receptor antagonist and...
|
|
|
5629349 |
Compounds for modulating growth of infectious agents
A method for modulating both in vivo and/or in vitro bacterial growth by administration of neurochemicals is disclosed. This method involves the recognition of a novel receptor for these compounds...
|
|
|
5597809 |
Treatment of optic neuritis
Methods of treating optic neuritis comprising administering a protective agent which inhibits glutamate-mediated retinal cell damage to a mammal at risk of developing optic neuritis.
|
|
|
5561129 |
Methods of administering phenothiazines and/or acid addition salts thereof
A method of administering phenothiazines and their acid addition salts. The phenothiazine or acid addition salt is injected intramuscularly in a formulation with a pH of about 5.5 to about 7.0 and...
|
|
|
5545614 |
Controlling nitrogen oxide concentrations to modulate skeletal muscle contraction
A method for inhibiting or relaxing skeletal muscle contractions and for treating disease states resulting from or exacerbated by undesirable skeletal muscle contractions by administering a...
|
|
|
5516789 |
Lipoxygenase and cyclooxygenase inhibiting compounds
Compounds having the structure ##STR1## or a pharmaceutically acceptable salt thereof have activity as inhibitors of cylooxygenase and 5-lipoxygenase, reduce the biosynthesis of leukotrienes B 4 ,...
|
|
|
5502049 |
Use of phenothiazine derivatives in the treatment of ischaemia and/or hypoxia
This invention relates to a novel therapeutical use of phenzothiazine derivatives of general formula (I), ##STR1## wherein R is a straight or branched chain C 1 -5 alkyl radical, and R 1 and R 2 ,...
|
|
|
5496818 |
Stable emulsion suitable for pharmaceutical administration, the production thereof and emulsion for pharmaceutical use
A stable active substance emulsion of the oil-in-water type with a phospholipid as emulsifier is described, where the active substance dissolved in the lipid phase has one or more basic groups, is...
|
|
|
5489590 |
Method of treating with therapeutic composition comprising photoactive compound
A therapeutic composition derived from a pre-activated photoactive compound and a conveyor for destroying tumor or other pathogenic biological contaminants infecting animal body tissues. The...
|
|
|
5330981 |
Arylalkyl esters of 4,5-dihydroxy-9,10-dihydro-9,10-dioxo-2-anthracenecarboxylic acid having therapeutical activity
This application describes 3-arylalkyl esters of 4,5-dihydro-9,10-dioxo-2-anthracenecarboxylic acid and a process for making them. Also described is a method of using the compounds in the treatment...
|
|
|
5322847 |
Azabenzimidazoles in the treatment of asthma, arthritis and related diseases
A series of imidazo[4,5-c]pyridines which inhibit platelet activating factor (PAF) and also block leukotriene D4 receptors are useful in treating asthma, arthritis, psoriasis, gastrointestinal...
|
|
|
5290775 |
Euthanasia compositions
An euthanasia solution based upon gamma-hydroxybutramide, a cardiotoxic amount of a compound selected from a chloroquine and quinacrine compound and lidocaine as a base or as a water soluble salt...
|
|
|
5262431 |
Prolinal derivatives and pharmaceutical compositions thereof
A novel prolinal derivative of general formula: ##STR1## [wherein A represents a group of the general formula: ##STR2## (wherein one of R 1 and R 2 represents hydrogen atom and the other...
|
|
|
5177073 |
Therapeutic compositions derived from photoactive compounds
A therapeutic composition derived from a pre-activated photoactive compound and a conveyor for destroying tumor or other pathogenic biological contaminants infecting animal body tissues. The...
|
|
|
5169846 |
Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
A non-aqueous micellar solution, for use in animal health, of one or more non water-soluble Anthelmintics and or insect growth regulators in a polyethoxylated oil or fat surfactant and one or more...
|
|
|
5137712 |
Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent supersensitivity, tolerance and extrapyramidal side effects induced by neuroleptic treatment
A method for reversing or preventing the onset of tolerance and the development of extrapyramidal side effects in humans due to prolonged treatment with neuroleptics, comprising including...
|
|
|
5130412 |
Electrochemical drug release and article
An electrically conducting self-doped carbazole polymer of the formula: ##STR1## wherein A is a bifunctional molecule capable of bonding to a positively charged molecule at one end and is capable...
|
|
|
5091385 |
Pre-activated therapeutic agents derived from photoactive compounds
A pre-activated therapeutic agent derived from a photoactive compound for destroying tumor or other pathogenic biological contaminants infecting animal body tissues. The activation of the...
|
|
|
5049669 |
Analgesic phenothiazine derivatives
Phenothiazine derivatives of general formula (I), in which R is a linear or branched (1 to 6 C) alkyl radical and R 1 and R 2 , which may be identical or different, are linear or branched (1 to 4...
|
|
|
5047403 |
Method for the reduction of heat distress induced nicarbazin toxicity in fowl
There is disclosed a method for the reduction of a toxicity resulting from the use of nicarbazin in fowl during periods of high heat distress. The method involves the administration of...
|
|
|
5036067 |
Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
Compounds having the formula I: ##STR1## are inhibitors of the 5-lipoxygenase enzyme. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They...
|
|
|
5032588 |
Thiazole lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids
Compounds of the formulae: ##STR1## and pharmaceutically acceptable salts, esters and prodrugs thereof, wherein M and R 1 are independently selected from among optionally substituted alkyl,...
|